Lauren Flores, NP
Nurse Practitioner · Sunnyvale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
Offices
1 location · Infusion Express of California Inc · 24 clinicians in this group
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Lauren Flores’s office at (408) 228-3700 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
Original Medicare doctor bills
$3,208,822
Medicare paid this office $3,208,822 for 260 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, ocrelizumab, 1 mg | 11 | $336,417 | None |
| Injection, vedolizumab, intravenous, 1 mg | 22 | $319,356 | None |
| Injection, tocilizumab, 1 mg | 15 | $207,718 | None |
| Injection, benralizumab, 1 mg | 12 | $161,227 | None |
| Injection, inclisiran, 1 mg | 40 | $158,933 | None |
See all 17 services
| Injection, ocrelizumab, 1 mg | 11 | $336,417 | None |
| Injection, vedolizumab, intravenous, 1 mg | 22 | $319,356 | None |
| Injection, tocilizumab, 1 mg | 15 | $207,718 | None |
| Injection, benralizumab, 1 mg | 12 | $161,227 | None |
| Injection, inclisiran, 1 mg | 40 | $158,933 | None |
| Injection, omalizumab, 5 mg | 15 | $121,948 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 13 | $105,785 | None |
| Injection, golimumab, 1 mg, for intravenous use | 13 | $70,815 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 15 | $50,283 | None |
| Administration of chemotherapy into vein, 1 hour or less | 111 | $36,007 | $117 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 43 | $10,292 | $56 |
| Injection of drug or substance under skin or into muscle | 110 | $4,382 | $12 |
| Administration of chemotherapy into vein, each additional hour | 33 | $2,011 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $1,218 | $18 |
| Injection of additional new drug or substance into vein | 30 | $837 | $13 |
| Injection, methylprednisolone sodium succinate, 5 mg | 22 | $235 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 12 | $10 | None |
Who their Medicare patients are
260 Original Medicare patients in 2024. Average age 72 · Under 65 14% · 85 and older 9% · Women 54% · Also on Medicaid 24% · Health risk score 1.47. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 37% · Coronary heart disease 28% · Chronic kidney disease 26% · COPD 22% · Depression 16% · Heart failure 14% · Atrial fibrillation 13% · Cancer 11% · Stroke 9%.
The office billed $11,474,429, Medicare allowed $4,034,067 and paid $3,208,822; for 171,989 services of 54 kinds; $3,122,370 of it was for drugs given in the office and $86,452 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 260 | 171,989 | 72 | 1.47 | $11,474,429 | $3,208,822 |
| 2023 | 60 | 10,808 | 72 | 1.19 | $1,081,893 | $341,492 |
| 2022 | 115 | 53,909 | 71 | 1.30 | $5,241,232 | $1,368,734 |
| 2021 | 60 | 5,416 | 72 | 1.10 | $546,029 | $145,305 |
| 2020 | 52 | 115 | 75 | 0.86 | $5,125 | $4,316 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Injection, omalizumab, 5 mg | 12 | $17,506 | None |
| Administration of chemotherapy into vein, 1 hour or less | 28 | $3,554 | $118 |
| Administration of chemotherapy into vein, each additional hour | 12 | $467 | $25 |
| Injection of drug or substance under skin or into muscle | 24 | $423 | $12 |
2022: 8 services
| Injection, omalizumab, 5 mg | 15 | $106,708 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $49,542 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 47 | $8,474 | $60 |
| Administration of chemotherapy into vein, 1 hour or less | 24 | $5,001 | $119 |
| Injection of drug or substance under skin or into muscle | 45 | $2,220 | $12 |
| Administration of chemotherapy into vein, each additional hour | 20 | $1,303 | $25 |
| Injection of additional new drug or substance into vein | 12 | $456 | $14 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 12 | $207 | None |
2021: 4 services
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $1,096 | $64 |
| Influenza vaccine split virus, preservative free | 12 | $572 | $48 |
| Injection of drug or substance under skin or into muscle | 13 | $304 | $11 |
| Administration of influenza virus vaccine | 12 | $223 | $19 |
2020: 2 services
| Influenza vaccine split virus, preservative free | 42 | $1,848 | $44 |
| Administration of influenza virus vaccine | 43 | $900 | $21 |
Medicaid work
$6,850 in 2024
Medicaid paid $6,850 for 83 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 83 | $6,850 |
| 2024 | 83 | 1 | 15 | $6,850 |
Money from drug and device companies
$320 in 2025
| 2025 | 4 | 5 | None | $320 |
| 2024 | 2 | 2 | None | $151 |
| 2023 | 1 | 1 | None | $29 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Lundbeck | Vyepti | $155 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $121 | 1 payment
|
| Octapharma USA | Octagam Immune Globulin (Human) | $27 | 1 payment
|
| Fresenius Kabi USA | None | $17 | 1 payment
|
See all 5 published payments
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-11 | Xifaxan | $121 |
| Octapharma USA | Meals · 2025-06-04 | Octagam Immune Globulin (Human) | $27 |
| Fresenius Kabi USA | Meals · 2025-02-20 | None | $17 |
| Lundbeck | Meals · 2025-01-29 | Vyepti | $30 |
| Lundbeck | Meals · 2025-01-16 | Vyepti | $125 |
See earlier years (2024, 2023)
2024: $151
| Argenx US | Vyvgart Hytrulo | $125 | 1 payment
|
| Octapharma USA | Octagam Immune Globulin (Human) | $26 | 1 payment
|
2023: $29
| Lundbeck | Vyepti | $29 | 1 payment
|
Professional record
- NPI
- 1801435516
- Licence
- CA 95014037, MD R222743
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 1720 S Bascom Ave, Campbell, CA, 95008
- NPI first listed
- 2019-12-27
- NPI last updated
- 2020-07-07
- NPI record certified
- 2020-07-07
This is when the NPI record was last certified, not a medical board exam.